Molecular basis of Hurthle cell papillary thyroid carcinoma

被引:106
作者
Cheung, CC
Ezzat, S
Ramyar, L
Freeman, JL
Asa, SL
机构
[1] Univ Toronto, Dept Pathol & Lab Med, Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada
[2] Univ Toronto, Dept Med Endocrinol, Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada
[3] Univ Toronto, Dept Otolaryngol, Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada
关键词
D O I
10.1210/jc.85.2.878
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Among thyroid neoplasms, Hurthle cell tumors (HCTs) have traditionally been a distinct diagnostic category. Hurthle cell adenomas are encapsulated follicular lesions with benign behavior. Hurthle cell carcinomas exhibit unequivocal capsular and/or vascular invasion; they are aggressive tumors with a poor prognosis. Recently, Hurthle cell papillary thyroid carcinomas (PTCs) have been identified on morphological grounds. We hypothesize that a subset of HCTs represent PTC with clinical histological, and immunohistochemical features based on specific molecular events. ret/PTC gene rearrangements give rise to novel oncogenes that are unique to PTC. We studied a group (n = 50) of HCTs for ret/PTC gene rearrangements. Tumors were examined for papillary differentiation by Light microscopic evaluation of nuclear features, by RT-PCR for ret/PTC gene rearrangements, and by immunohistochemistry for ret. Among 24 noninvasive tumors, 13 contained ribonucleic acid for ret/PTC-1, -2, or -3, and 9 of these were immunoreactive for ret. Among 19 Hurthle cell carcinomas, 15 had focal nuclear hypochromasia with grooves and/or inclusions; expressed transcripts of ret/PTC-1, -2, or -3; and exhibited ret positivity. Tumors with ret/PTC gene rearrangements tended to have lymph node metastases rather than hematogenous spread. Our results indicate that a subset of HCTs exhibit features of PTC that are attributable to specific gene rearrangements, resulting in expression of ret/PTC oncogenes. These data support subclassification of HCTs into three groups: Hurthle cell adenomas, Hurthle cell carcinomas, and Hurthle cell PTC.
引用
收藏
页码:878 / 882
页数:5
相关论文
共 30 条
[11]  
HEDINGER C, 1989, CANCER-AM CANCER SOC, V63, P908, DOI 10.1002/1097-0142(19890301)63:5<908::AID-CNCR2820630520>3.0.CO
[12]  
2-I
[13]   HURTHLE CELL (OXYPHILIC) PAPILLARY THYROID-CARCINOMA - A VARIANT WITH MORE AGGRESSIVE BIOLOGIC BEHAVIOR [J].
HERRERA, MF ;
HAY, ID ;
WU, PSC ;
GOELLNER, JR ;
RYAN, JJ ;
EBERSOLD, JR ;
BERGSTRALH, EJ ;
GRANT, CS .
WORLD JOURNAL OF SURGERY, 1992, 16 (04) :669-675
[14]   HURTHLE CELL VARIANT OF PAPILLARY CARCINOMA OF THE THYROID-GLAND [J].
HILL, JH ;
WERKHAVEN, JA ;
DEMAY, RM .
OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 1988, 98 (04) :338-341
[15]  
ISHIZAKA Y, 1992, ONCOGENE, V7, P1441
[16]   Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas [J].
Jhiang, SM ;
Sagartz, JE ;
Tong, Q ;
ParkerThornburg, J ;
Capen, CC ;
Cho, JY ;
Xing, SH ;
Ledent, C .
ENDOCRINOLOGY, 1996, 137 (01) :375-378
[17]  
JHIANG SM, 1994, J LAB CLIN MED, V123, P331
[18]  
Klugbauer S, 1995, ONCOGENE, V11, P2459
[19]  
LANZI C, 1992, ONCOGENE, V7, P2189
[20]  
Nikiforov YE, 1997, CANCER RES, V57, P1690